Imatinib Ratiopharm

Imatinib, the active ingredient in Imatinib Ratiopharm, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It provides targeted therapy that blocks specific cellular pathways and treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide through its global distribution network, ensuring full regulatory compliance and reliable product quality.

Imatinib is a targeted tyrosine‑kinase inhibitor used in malignancies driven by BCR‑ABL or KIT signaling. - Chronic Myeloid Leukemia (CML): achieves inhibition of malignant cell proliferation and disease control. - Gastrointestinal Stromal Tumor (GIST): achieves tumor shrinkage and disease stabilization. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): provides targeted therapy to improve remission rates.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Peripheral edema - Fatigue - Diarrhea

Serious or Rare Side Effects: - Severe neutropenia - Hepatotoxicity - Cardiac failure

When prescribing Imatinib, clinicians should observe several precautionary measures to minimize risk. - Monitor blood counts: perform regular complete blood count assessments to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes before initiation and periodically during therapy. - Evaluate cardiac status: perform baseline and periodic cardiac function tests in patients with pre‑existing heart disease. - Review concomitant medications: avoid known major interacting drugs and adjust doses as needed. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Imatinib interacts with several medicines; understanding the level of interaction guides clinical decision‑making.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce imatinib exposure and efficacy. - Antacids containing aluminum or magnesium: can decrease oral absorption of imatinib.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may alter INR, requiring closer coagulation monitoring. - Loop diuretics: enhanced risk of fluid retention and edema. - QT‑prolonging agents: combined use may increase the risk of cardiac arrhythmias.